Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Eur J Pediatr ; 169(7): 801-11, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20013129

RESUMEN

Schimke immunoosseous dysplasia (SIOD) is an autosomal recessive multisystem disorder characterized by prominent spondyloepiphyseal dysplasia, T cell deficiency, and focal segmental glomerulosclerosis. Biallelic mutations in swi/snf-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1 (SMARCAL1) are the only identified cause of SIOD, but approximately half of patients referred for molecular studies do not have detectable mutations in SMARCAL1. We hypothesized that skeletal features distinguish between those with or without SMARCAL1 mutations. Therefore, we analyzed the skeletal radiographs of 22 patients with and 11 without detectable SMARCAL1 mutations. We found that patients with SMARCAL1 mutations have a spondyloepiphyseal dysplasia (SED) essentially limited to the spine, pelvis, capital femoral epiphyses, and possibly the sella turcica, whereas the hands and other long bones are basically normal. Additionally, we found that several of the adolescent and young adult patients developed osteoporosis and coxarthrosis. Of the 11 patients without detectable SMARCAL1 mutations, seven had a SED indistinguishable from patients with SMARCAL1 mutations. We conclude therefore that SED is a feature of patients with SMARCAL1 mutations and that skeletal features do not distinguish who of those with SED have SMARCAL1 mutations.


Asunto(s)
Huesos/diagnóstico por imagen , ADN Helicasas/genética , Mutación , Osteocondrodisplasias/diagnóstico por imagen , Osteocondrodisplasias/genética , Adolescente , Adulto , Niño , Preescolar , Diagnóstico Diferencial , Heterogeneidad Genética , Glomeruloesclerosis Focal y Segmentaria/genética , Humanos , Linfopenia/genética , Fenotipo , Radiografía , Síndrome
2.
Artículo en Inglés | MEDLINE | ID: mdl-18401198

RESUMEN

Fabry disease is an X-linked inherited disorder of glycosphingolipid metabolism due to the deficient activity of a lysosomal enzyme, alpha-galactosidase A. The resultant systemic accumulation of sphingolipids can lead to progressive and sudden hearing loss alongside renal, cardiac and cerebrovascular complications. Although replacement therapy seems to be beneficial for cochlear function, few data are available regarding treatment of sudden hearing loss. This case report describes the course of a unilateral sudden hearing loss in a young (15-year-old) male patient and its improvement following hyperbaric oxygen treatment.


Asunto(s)
Enfermedad de Fabry/complicaciones , Pérdida Auditiva Súbita/etiología , Pérdida Auditiva Súbita/terapia , Pérdida Auditiva Unilateral/etiología , Pérdida Auditiva Unilateral/terapia , Oxigenoterapia Hiperbárica , Adolescente , Audiometría , Audiometría del Habla , Enfermedad de Fabry/fisiopatología , Audición , Pérdida Auditiva Súbita/diagnóstico , Pérdida Auditiva Unilateral/diagnóstico , Humanos , Masculino , Recuperación de la Función , Resultado del Tratamiento
3.
Hum Mutat ; 28(3): 273-83, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17089404

RESUMEN

Schimke immunoosseous dysplasia (SIOD), which is characterized by prominent spondyloepiphyseal dysplasia, T-cell deficiency, and focal segmental glomerulosclerosis, is a panethnic autosomal recessive multisystem disorder with variable expressivity. Biallelic mutations in switch/sucrose nonfermenting (swi/snf) related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1 (SMARCAL1) are the only identified cause of SIOD. However, among 72 patients from different families, we identified only 38 patients with biallelic mutations in the coding exons and splice junctions of the SMARCAL1 gene. This observation, the variable expressivity, and poor genotype-phenotype correlation led us to test several hypotheses including modifying haplotypes, oligogenic inheritance, or locus heterogeneity in SIOD. Haplotypes associated with the two more common mutations, R820H and E848X, did not correlate with phenotype. Also, contrary to monoallelic SMARCAL1 coding mutations indicating oligogenic inheritance, we found that all these patients did not express RNA and/or protein from the other allele and thus have biallelic SMARCAL1 mutations. We hypothesize therefore that the variable expressivity among patients with biallelic SMARCAL1 mutations arises from environmental, genetic, or epigenetic modifiers. Among patients without detectable SMARCAL1 coding mutations, our analyses of cell lines from four of these patients showed that they expressed normal levels of SMARCAL1 mRNA and protein. This is the first evidence for nonallelic heterogeneity in SIOD. From analysis of the postmortem histopathology from two patients and the clinical data from most patients, we propose the existence of endophenotypes of SIOD.


Asunto(s)
Variación Genética , Síndromes de Inmunodeficiencia/genética , Osteocondrodisplasias/genética , Algoritmos , Niño , Preescolar , ADN Helicasas/genética , Análisis Mutacional de ADN , Femenino , Pruebas Genéticas , Humanos , Lactante , Recién Nacido , Masculino , Fenotipo
4.
J Dtsch Dermatol Ges ; 5(7): 594-7, 2007 Jul.
Artículo en Inglés, Alemán | MEDLINE | ID: mdl-17610610

RESUMEN

A 38-year-old male Caucasian with Fabry disease presented with angiokeratomas and tortuous conjunctival and retinal vessels. Additionally, the patient showed characteristic skin lesions of psoriasis and seborrheic dermatitis. His past medical history revealed anhidrosis, acral paresthesias, myocardial infarction, phlebothrombosis, hypertension, antithrombin III deficiency, factor V Leiden disease, chronic obstructive lung disease, tinnitus, diarrhea, recurrent abdominal pain, headache, and depressive mood. He was treated with intravenous substitution of the deficient enzyme alpha-galactosidase A. Possible future options in treatment of Fabry disease are discussed.


Asunto(s)
Enfermedad de Fabry/tratamiento farmacológico , Enfermedad de Fabry/patología , alfa-Galactosidasa/uso terapéutico , Adulto , Humanos , Masculino , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA